Praxis Precision Medicines Inc.

Address: 99 High Street Floor 30th

Sponsor Overview

assignment

Specializations

Epilepsy and Seizure Disorders

Clinical research focuses on adult epilepsy, including focal epilepsy and primary generalized tonic-clonic seizures, with attention to seizure control and treatment response in people using background anti-seizure medications.

Focal onset seizures
Primary generalized tonic-clonic seizures
Seizure frequency

The sponsor also studies photoparoxysmal electroencephalogram response in epilepsy, reflecting interest in seizure-related neurophysiological markers.

Developmental and Epileptic Encephalopathies

Research extends to severe pediatric developmental and epileptic encephalopathies, with a particular focus on SCN2A and SCN8A-related disease.

SCN2A-DEE
SCN8A-DEE
Early-onset epileptic syndromes

These studies address countable motor seizures and broader seizure burden in children with genetically defined epileptic disorders.

Ion Channel-Related Neurology

The sponsor has a clear therapeutic interest in voltage-gated sodium channel biology, especially conditions linked to SCN2A and SCN8A dysfunction.

SCN2A developmental and epileptic encephalopathy
Sodium channel dysfunction
Neurogenetic epilepsy

This area includes research in both adult and pediatric populations with inherited seizure disorders.

Therapeutic Development in Seizure Control

Current trials explore investigational treatments for focal seizures, focal onset seizures, and tonic-clonic seizures, alongside treatment assessment in participants receiving existing anti-seizure therapy.

Adjunctive seizure treatment
Adult seizure management
Pediatric seizure disorders

Research activity also includes evaluation of drug-drug interaction potential in support of neurological treatment development.

Sponsored Trials

Trial Name	Country	Status
A Phase 2, Double-Blind, Randomized Clinical Trial to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of PRAX-562 in Pediatric Participants with Developmental and Epileptic Encephalopathies Followed by an Open-Label Extension	Spain	Not Recruiting
Efficacy and Safety Evaluation of Elsunersen in Pediatric Patients with Early-Onset SCN2A Developmental and Epileptic Encephalopathy	Germany Italy	Recruiting
Efficacy and Safety Evaluation of PRAX-628 in Adults with Focal Epilepsy: A Double-Blind, Randomized, Multicenter Trial	Italy Poland Spain	Not Recruiting
Efficacy and Safety of Vormatrigine in Adults with Focal Epilepsy Receiving Concomitant Antiseizure Medications: A Randomized, Double-Blind, Placebo-Controlled Trial	Czechia Germany Italy Poland Spain	Not Yet Recruiting
Evaluation of Drug-Drug Interaction Potential of PRAX-628 in a Phase 1, Open-Label, Multiple-Part Trial in Healthy Participants with Epilepsy	The Netherlands	Not Recruiting
Evaluation of PRAX-628 Efficacy and Safety in Adults with Focal Onset or Primary Generalized Tonic-Clonic Seizures: An Open-Label Clinical Trial	Germany Spain	Not Recruiting
Evaluation of PRAX-628 on Photoparoxysmal EEG Response in Epilepsy Patients with Intermittent Photic Stimulation: A Phase 2, Single-Blind, Placebo-Controlled Study	The Netherlands	Not Recruiting
Evaluation of Vormatrigine and PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures: An Open-Label Extension Study	Germany Italy Poland Spain	Recruiting